Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080340 · ClinicalTrials.gov registry record · Phase 3
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 3 study of Non-Small-Cell Lung Carcinoma, sponsored by Telik.
- Completed
- Registry status
- Phase 3
- Development phase
- 520
- Enrollment target
- 20
- Study locations
NCT00080340: Completed Phase 3 study of Non-Small-Cell Lung Carcinoma, sponsored by Telik.
NCT00080340 is a Phase 3 study of Non-Small-Cell Lung Carcinoma that has completed, run by Telik. The registered enrollment target is 520 participants, above the 218-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (139% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00080340, a Phase 3 study of Non-Small-Cell Lung Carcinoma, has completed, sponsored by Telik.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 520 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG TLK286 (Telcyta) HCl for Injection
- DRUG gefitinib (Iressa)
Study Locations (20)
California
- East Bay Medical Oncology/Hematology Medical Associates, Inc. - Antioch
- East Valley Hematology Oncology Medical Group - Burbank
- Providence Saint Joseph Medical Center - Burbank
- Marilyn Norton, M. D. - Chula Vista
- Rosalba Rodriquez, M. D. - Chula Vista
- Bay Area Cancer Research Group - Concord
- Wilshire Oncology Medical Group, Inc. - Glendora
- Grossmont Hospital - La Mesa
- Sharp Rees-Stealy - La Mesa
Arkansas
- Little Rock Hematology Oncology Benton - Benton
- Highlands Oncology Group - Bentonville
- Highlands Oncology Group - Fayetteville
- Heritage Physician Group, Oncology - Hot Springs
- University of Arkansas for Medical Sciences - Little Rock
- Highlands Oncology Group - Springdale
Alabama
- UAB CCC Clinical Studies Unit - Birmingham
- Department of Veterans Affairs Medical Center - Birmingham
- University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham - Birmingham
Arizona
- Palo Verde Hematology Oncology - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Est. Completion | 2005-05 |
| Phase | Phase 3 |
What the finished NCT00080340 record still lists
NCT00080340 is an interventional study that assigns participants to a tested intervention. The registered 520 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (139% higher).
The record links to 1 condition, with Non-Small-Cell Lung Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which TLK286 (Telcyta) HCl for Injection is the first listed.
NCT00080340 names 20 study sites across 4 states, led by California, Arkansas, Alabama.
Frequently Asked Questions
What is clinical trial NCT00080340 about?
NCT00080340 is a clinical study titled "Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer". The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.
What is the current status of trial NCT00080340?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 520 participants. Estimated completion is 2005-05.
What conditions does trial NCT00080340 study?
This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma.
What interventions are being tested in trial NCT00080340?
The interventions under investigation include: TLK286 (Telcyta) HCl for Injection (DRUG), gefitinib (Iressa) (DRUG).
Who is sponsoring clinical trial NCT00080340?
This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00080340 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small-Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00080340's enrollment target sits among peer trials
520 5th of 30 higher than 26 of 30 other Non-Small-Cell Lung Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small-Cell Lung Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RECRUITING · Phase 3
-
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
COMPLETED · Phase 3
-
Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer
COMPLETED · Phase 3
-
Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2
COMPLETED · Phase 3
-
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
RECRUITING
-
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
- NCT04656496 · 520 participants · NA
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
- NCT05445778 · 520 participants · Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
- NCT05498428 · 520 participants · Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer